Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Gets Price Target Reduction from Citigroup

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price decreased by Citigroup from $108.00 to $105.00 in a report issued on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the biotechnology company’s stock.

ARWR has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. Stifel Nicolaus reduced their price objective on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. B. Riley Financial boosted their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, November 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $98.71.

Get Our Latest Stock Report on ARWR

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $43.65 on Tuesday. The company has a quick ratio of 4.11, a current ratio of 4.14 and a debt-to-equity ratio of 16.61. Arrowhead Pharmaceuticals has a 52-week low of $37.06 and a 52-week high of $95.49. The company has a 50 day moving average of $60.06 and a two-hundred day moving average of $70.49. The company has a market cap of $6.17 billion, a P/E ratio of -8.54 and a beta of 1.34.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Optiver Holding B.V. raised its stake in Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in Arrowhead Pharmaceuticals during the second quarter valued at approximately $39,000. Finally, Allied Private Wealth LLC acquired a new stake in Arrowhead Pharmaceuticals during the second quarter valued at approximately $43,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Further Reading

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.